Hernia Reduction Prior to Scheduled TIF Completion

Stopped early · Not applicable

Conditions studied: Fundoplication

In brief

Hernia Reduction Prior to Scheduled TIF Completion using EsophyX ZR transoral device

Key facts

Study ID

NCT03280121

Run by

EndoGastric Solutions

People needed

14

Starts

2018-10-05

Expected to finish

2020-10-26

Last updated by the study team

2021-02-10

Who can join

Age: 18 and older, up to 72. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18-72 years
• Dependent upon daily PPIs for > 6 months. Daily use is defined as a double dose, or full dose or half dose taken daily for more than 80% of the total number of days during the proceeding evaluation period
• Troublesome symptoms, specifically heartburn or regurgitation, while on optimized dose of PPI's Troublesome heartburn or regurgitation symptoms are those which occur a minimum of 2 days a week and are mild to severe in severity
• Abnormal ambulatory (Bravo) pH study after off PPI therapy for 7 days, i.e. > 5.3% of the time with pH < 4 in a 48-hour monitoring period
• Normal or near normal esophageal motility (by Upper GI/ esophagram or manometry as required)
• Pre-enrollment Hiatal Hernia (axial height and transverse dimension) from > 2 cm up to 4 cm inclusive.
• Patient willing to cooperate with post-operative dietary recommendations and assessment tests at the requisite follow-up visits
• Signed informed consent Exclusion Criteria
• BMI > 35 2. Hiatal hernia ≤ 2 and > 4 cm 3. Esophagitis Los Angeles grade C or D 4. Esophageal ulcer 5. Esophageal stricture 6. Long-segment Barretts esophagus (Prague: C > 1, M > 3) 7. Esophageal motility disorder 8. Pregnancy or plans for pregnancy in the next 12 months (in females) 9. Immunosuppression 10. ASA > 2 11. Portal hypertension and/or varices 12. History of previous resective gastric or esophageal surgery, cervical spine fusion, Zenker's diverticulum, esophageal epiphrenic diverticulum, achalasia, scleroderma or dermatomyositis, eosinophilic esophagitis, or cirrhosis 13. Active gastro-duodenal ulcer disease 14. Gastric outlet obstruction or stenosis 15. Severe gastroparesis or delayed gastric emptying confirmed by solid-phase gastric emptying study if patient complains of postprandial satiety during assessment 16. Coagulation disorders 17. Atypical symptoms including gas bloat and dysphagia. 18. Any other presenting condition that in the opinion of the investigator would not make participation in this study in the patient's best interest.
• Post Enrollment Exclusion -
• Inability to repair Hiatal hernia with at least 2cm of intra-abdominal esophagus length.

Where it is running

• Elkhart General Hospital — Elkhart, Indiana, United States
• Aspirus Iron River Hospital — Iron River, Michigan, United States
• Northern Nevada Medical Center — Sparks, Nevada, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.